Collegium Pharmaceutical Inc Stock Price, News & Analysis

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has announced the pricing of a private offering of $210 million in 2.875% convertible senior notes due 2029, up from a previously projected $175 million. The notes are expected to settle on February 10, 2023. The initial conversion price is approximately $36.56 per share, which represents a premium of about 30% over the last stock price of $28.12 on February 7, 2023. The net proceeds are estimated at $203.2 million, aimed at repurchasing $117.4 million of 2026 notes and for general corporate purposes. The offering includes options for initial purchasers to buy an additional $31.5 million of notes.

Collegium Pharmaceutical (Nasdaq: COLL) plans to offer $175 million in convertible senior notes due 2029. The offering is private, intended for qualified institutional buyers, with an additional $26.25 million option for initial purchasers. The notes will accrue interest and can be converted into cash or common stock. Collegium aims to use proceeds to repurchase part of its 2026 Convertible Senior Notes and for general corporate purposes, including working capital and business development. The company has not set specific uses beyond the repurchase of 2026 notes and has no current acquisition agreements.

Collegium Pharmaceutical (Nasdaq: COLL) reported preliminary financial results for Q4 and FY 2022, estimating product revenues of $460.0-$462.5 million for the year and $125.7-$128.2 million for Q4. GAAP operating expenses are projected between $176.5-$181.5 million for the year and $38.4-$43.4 million for the fourth quarter. Adjusted EBITDA is expected to be $261.5-$264.0 million for the year and $71.9-$74.4 million for Q4. The company announced its final results will be disclosed on February 23, 2023, after market close. These results exceed the high-end of their previously issued earnings guidance for 2022.

Collegium Pharmaceutical (Nasdaq: COLL) has announced its financial guidance for 2023, projecting net product revenues between $565 million and $580 million. Adjusted operating expenses are expected to range from $135 million to $145 million, while adjusted EBITDA is forecasted to be between $355 million and $370 million. Notably, the board has authorized a $100 million share repurchase program following a $19.1 million return to shareholders in 2022. The Federal Circuit upheld critical patents for Belbuca, ensuring market exclusivity until 2032.

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced that the Federal Circuit upheld the validity of certain patents for Belbuca, blocking ANDA filer Alvogen from entering the market until 2032. The ruling confirms the strength of the company’s patents, including the '866 patent expiring in 2027 and the '539 patent set to expire in 2032. Alvogen conceded infringement on all claims, benefitting Collegium by ensuring Belbuca remains exclusively marketed until the patents expire.

Collegium Pharmaceutical (Nasdaq: COLL) announced participation in the Piper Sandler 34th Annual Healthcare Conference in New York from November 29 to December 1, 2022. Management will engage in a fireside chat on November 30, 2022, at 1:30 p.m. ET. The discussion will be webcast live and accessible via the Investors section of Collegium's website, with a replay available for 90 days post-event. Collegium is dedicated to enhancing the lives of individuals with serious medical conditions, headquartered in Stoughton, Massachusetts.

Collegium Pharmaceutical reported record net revenue of $127.0 million for Q3 2022, up from $78.8 million in Q3 2021. The company successfully renegotiated contracts for Xtampza® ER, achieving a gross-to-net less than 65% starting January 2023. Collegium returned $10 million to shareholders through repurchases. The updated full-year guidance estimates total product revenues between $455.0 and $465.0 million and adjusted EBITDA from $250.0 to $255.0 million. The company exited Q3 with $134.1 million in cash, highlighting strong operational performance.

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) is set to report its third quarter 2022 financial results on November 3, 2022, after market close. A live conference call will follow at 4:30 p.m. ET, accessible via telephone or webcast. Collegium continues to focus on its commitment to improving the lives of those with serious medical conditions, based in Stoughton, Massachusetts. For further details, listeners can access the webcast on the company’s website shortly after the event.

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced 11 poster presentations at the Annual PAINWeek National Conference from September 6-9, 2022, in Las Vegas. These presentations showcase data on its differentiated products, particularly Xtampza® ER and Celecoxib Oral Solution. Dr. Thomas Smith highlighted the opportunity to share clinical insights, emphasizing the company's commitment to enhancing patient care for serious medical conditions. The research details the efficacy and safety of treatments while addressing risks like addiction and cardiovascular issues associated with their products.